Journal of Clinical and Translational Hepatology

Journal of Clinical and Translational Hepatology

Friday, 09 / 21 / 2018

Articles

Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B

GUIDELINES & CONSENSUS

Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B

Wenhong Zhang#,1, Dazhi Zhang#,2, Xiaoguang Dou3, Qing Xie4, Jiaji Jiang5, Xinyue Chen6 and Hong Ren*,2

1Huashang Hospital of Fudan University, Shanghai, China
2The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
3Shengjing Hospital of China Medical University, Shenyang, China
4Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
5First Affiliated Hospital, Fujian Medical University, Fuzhou, China
6You An Hospital, Capital Medical University, Beijing, China

#Wenhong Zhang and Dazhi Zhang contributed equally to the article.

*Correspondence to: Hong Ren, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal of Clinical and Translational Hepatology 2018;6(1):1-10 DOI: 10.14218/JCTH.2017.00073
Received: November 8, 2017 Accepted: February 9, 2018 Published online: March 17, 2018

Introduction

As advice and consensus on the pegylated-interferon (Peg-IFN) treatment for chronic hepatitis B (CHB) in China, the Expert Advice on Peg-IFN Treatment for CHB was published in the Chinese Journal of Infectious Diseases in 2007, and updated in 2010 and 2012.1,2 Previous versions of the Expert Advice described optimized patients for Peg-IFN treatment (baseline guided therapy; BGT), basic principles of treatment adjustment according to the response to the therapy (response guidance therapy; RGT), dosage adjustment based on adverse effects and symptomatic treatment towards adverse reactions. As a supplement to clinical guidelines of CHB management, Expert Advice has deepened clinicians’ awareness of individualized Peg-IFN treatment for CHB patients, playing a positive role in guiding the rational use of interferon.

Seeing as the last update of Expert Advice, following the revised version of China’s CHB Prevention and Treatment Guidelines and international guidelines for the treatment of CHB and expanded clinical research, new evidence from evidence-based medicine and a new concept of Peg-IFN in the treatment of CHB has motivated us to review the previous version of Expert Advice. In 2017, the expert group, under the premise of conforming with the principle of Expert Advice, refined and supplemented some of the suggestions and explored hot issues related to the current Peg-IFN treatment, forming a new version of Expert Consensus on Peg-IFNα in the Treatment of CHB to further standardize the clinical use and improve the efficacy of Peg-IFN therapy to achieve treatment goals.

 

Journal of Clinical and Translational Hepatology 2018 vol. 6, 1-10  Html ] [ PDF Full-text ]

© The Authors 2018. This article is published under the terms of the Creative Commons Attribution-Noncommercial License (CC BY-NC 4.0), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

 

 logo

You are here: Home